Research progress on immunogenicity of PEGylated recombinant human granulocyte-colony stimulating factor
10.13200/j.cnki.cjb.004280
- VernacularTitle:聚乙二醇化重组人粒细胞集落刺激因子免疫原性的研究进展
- Author:
WANG Danyang
- Publication Type:Journal Article
- Keywords:
Recombinant human granulocyte-colony stimulating factor(rhG-CSF);
Polyethylene glycol(PEG);
Immunogenicity;
Antidrug antibody(ADA);
Adverse reactions
- From:
Chinese Journal of Biologicals
2024;37(8):1002-1007
- CountryChina
- Language:Chinese
-
Abstract:
Recombinant human granulocyte-colony stimulating factor(rhG-CSF)can effectively prevent and treat febrile neutropenia caused by chemotherapy,which mainly metabolizes through the kidneys and has a short half-life,requiring repeated injections to maintain its effect. PEG-rhG-CSF formed by combining polyethylene glycol(PEG)with rhG-CSF can prolong the half-life of drugs. However,there have been immunogenicity mediated adverse reactions in clinical use of PEGrhG-CSF,and the safety is still the focus of attention. This paper discusses the adverse reactions induced by PEG-rhG-CSF immunogenicity,as well as the influencing factors,detection methods and production mechanism of immunogenicity with the aim of providing reference for the safe clinical application of PEG-rhG-CSF.
